Calyxt

Calyxt, Inc. is technology company. engages in delivering plant-based solutions. Its products include high oleic soybean oil, high fiber wheat, high oleic soybean meal, and low lignin alfalfa. The company was founded by Daniel F. Voytas and André Choulika on January 8, 2010 and is headquartered in Roseville, MN.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cibus, Inc. engages in the research and development of plant traits to seed companies for royalties. It focuses on using gene editing to develop productivity traits in major agricultural crops such as Canola, Rice, Soybean, Corn and Wheat. The company was founded by Rory Riggs, Peter Beetham and Greg Gocal in 2010 and is headquartered in San Diego, CA.

ROSEVILLE, Minn., July 15, 2021 /PRNewswire/ -- Calyxt, Inc.  (NASDAQ: CLXT), a plant-based biotechnology platform company, today announced the appointment of Michael A.

Calyxt Appoints Michael A. Carr as Chief Executive Officer

Triploid Breeding Process is Calyxt's Second Announced Advancement and Part of a Comprehensive Approach to Improving Hemp Genetics ROSEVILLE, MN / ACCESSWIRE / July 8, 2021 / Calyxt, Inc. (NASDAQ:CLXT), today announced further expansion of its hemp breeding platform with the addition of triploid breeding technology to create seedless hemp. Bringing this technology to hemp cultivation comes on the heels of the company announcing the successful transformation of the hemp genome.

Calyxt Announces Expansion of Hemp Breeding Platform with Seedless Hemp Innovation

Beam Therapeutics

Cellectis SA

CRISPR Therapeutics

Editas Medicine

Intellia Therapeutics

Sangamo Therapeutics

Doudna's breakthrough in CRISPR has since ushered in a new era of genetic engineering, making these the best gene-editing stocks to buy. The post The Top 7 Gene-Editing Stocks to Buy for the Biggest Scientific Breakthrough of the Century appeared first on InvestorPlace.

The Top 7 Gene-Editing Stocks to Buy for the Biggest Scientific Breakthrough of the Century

Calyxt is a plant-technology company that develops plant-based innovations and solutions aiming to disrupt a broad group of industries. Calyxt is a leading gene-editor with exclusive access to the parent company's proprietary TALEN technology for use in plants which resulted in the first successfully US-commercialized gene-edited food product.

Calyxt: Proprietary TALEN Plant-Technology Offers Multi-Industry Growth

Calyxt, Inc. (CLXT) Q1 2021 Results - Earnings Call Transcript

Early-Stage Validation that Next Generation Premium Soybean Product Performance is Best-in-Class for High Oleic, Ultra-Low Linolenic Profile Successful Transformation of Hemp Genome Enables Step Change in Calyxt's Innovation Approaches in the Species Promoted Sarah Reiter to the newly created role of Chief Business Officer Scientific Advisory Board Formed, Diverse Scientific Expertise, and Proprietary Insights to Support Company Growth Management to Host Conference Call Today at 4:30 p.m. ET ROSEVILLE, MN / ACCESSWIRE / May 6, 2021 / Calyxt, Inc. (NASDAQ:CLXT), a plant-based technology company, today announced financial results for its first quarter ended March 31, 2021.

Calyxt Reports First Quarter 2021 Financial Results

Next Generation Premium Soybean Product Line Contains Ultra-Low Levels of Linolenic Acid Positioning it to be the Most Stable Premium Soybean Oil Available on the Market R&D Advancement with Complex Plant Biological Pathways Enables Calyxt to Deliver Next Generation Plant-Based Solutions in Rapid Time Frame ROSEVILLE, MN / ACCESSWIRE / May 4, 2021 / Calyxt, Inc. (NASDAQ:CLXT), a plant-based technology company, announced today that its next generation premium high oleic low linolenic (HOLL) soybean oil trait has exceeded industry performance targets expected in the premium oil segment. This marks a step-improvement on Calyxt's first gene-edited product that was commercialized in the U.S. by delivering superior functional performance plus a -superior functional performance and fatty acid profile superior to other premium oils.

Calyxt Announces Next Generation Premium Soybean Product Line Performance Best-In-Class for High Oleic, Ultra-Low Linolenic Profile

New Hemp Transformation Technology Unlocks Capabilities to Selectively Breed and Deliver Improvements in Hemp Traits for Key Markets Including Protein, Fiber, Advanced Materials and Wellness Patent-Pending Transformation Process is Calyxt's First Announced Innovation in a Broad Hemp Improvement Pipeline ROSEVILLE, MN / ACCESSWIRE / April 29, 2021 / Calyxt, Inc . (NASDAQ:CLXT), a plant-based technology company, announced today that it has successfully transformed hemp genome, enabling a step-change in innovation approaches in the species.

Calyxt Successfully Transforms Hemp Genome

Thermo Fisher Scientific

Zymergen

Here's what to look for and what to steer clear of.

2 Risky Life-Sciences Stocks to Avoid and 1 to Buy Now

ROSEVILLE, MN / ACCESSWIRE / April 20, 2021 / Calyxt, Inc . (NASDAQ:CLXT), a plant-based technology company, will participate in the following investor and industry conferences during the month of May 2021: 2021 American Oil Chemists Society (AOCS) Annual Meeting & Expo Date: May 4, 2021 Time: 4:00 p.m.

Calyxt to Present at Upcoming Investor and Industry Conferences

Calyxt to Host First Quarter 2021 Financial Results Conference Call on Thursday, Ma y 6 , 202 1 at 4 :30 p .m. Eastern Time ROSEVILLE, MN / ACCESSWIRE / April 15, 2021 / Calyxt, Inc. (NASDAQ:CLXT), a plant-based technology company, will hold a conference call on Thursday, May 6, 2021 at 4:30 p.m.

Calyxt to Host First Quarter 2021 Financial Results Conference Call on Thursday, May 6, 2021 at 4:30 p.m. Eastern Time

Calyxt has changed its operating strategy to a more conventional agri-bio seed/trait model similar to those pursued by established agri-bio names like Bayer and Corteva. Calyxt is targeting new high-risk/high-reward market opportunities including winter oats, hemp, and soybeans with saturated fat content that could be a substitute for palm oil.

Calyxt Using A More Conventional Model To Pursue Significant New Agri-Bio Market Opportunities

Calyxt, Inc. (CLXT) Q4 2020 Results - Earnings Call Transcript

Calyxt (CLXT) delivered earnings and revenue surprises of -32.00% and 77.18%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Calyxt (CLXT) Reports Q4 Loss, Tops Revenue Estimates

-Shares of Calyxt (NASDAQ:CLXT) were flat after-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 10.81% year over year to ($0.33), which missed the estimate of ($0.22).

Recap: Calyxt Q4 Earnings

Continued to Progress Development of Winter Oats and Hemp, Both Targeted at Large Addressable Markets Secured Commitment from ADM to Purchase Remaining 2019 Grain Inventory and All 2020 Grain Production - Have Completed Sale of 40 Percent of 2020 Grain Crop Executed Commercial Agreement with S&W Seed Company on IQ™ Alfalfa Product, Marking Calyxt's First Trait License Agreement Management to Host Conference Call Today at 4:30 p.m. ET ROSEVILLE, MN / ACCESSWIRE / March 4, 2021 / Calyxt, Inc. (NASDAQ:CLXT), a plant-based technology company, has reported its financial results for the fourth quarter and full year ended December 31, 2020.

Calyxt Reports Fourth Quarter and Full Year 2020 Financial Results

Calyxt (CLXT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Should You Buy Calyxt (CLXT) Ahead of Earnings?

ROSEVILLE, MN / ACCESSWIRE / March 3, 2021 / Calyxt, Inc . (NASDAQ:CLXT), a plant-based technology company, will participate in the following investor conferences during the month of March 2021: Bank of America Securities 2021 Global Agriculture & Materials Virtual Conference Date: Wednesday, March 3, 2021 Time: 11:00 a.m.

Calyxt to Present at Upcoming March Investor Conferences

World-Renowned Plant-Biochemistry Experts Named to Calyxt's Scientific Advisory Board Chaired by Company Co-Founder Dan Voytas, Ph.D. New Strategic Initiative to Identify High Value Plant-Derived Products Utilizing Calyxt's Proprietary Innovation Platform ROSEVILLE, MN / ACCESSWIRE / March 2, 2021 /  Calyxt, Inc. (NASDAQ:CLXT), a plant-based technology company, has completed key appointments to its previously announced Scientific Advisory Board (SAB) to identify high value plant-derived product targets that will be produced utilizing Calyxt's proprietary innovation platform.

Calyxt Completes New Scientific Advisory Board with Key Appointments

Calyxt sells a premium soybean cooking oil Calyno   TALEN gene-editing technology is a game-changer   Strong management team with proven track record   What Calyxt does:  Calyxt Inc (NASDAQ:CLXT) is a plant-based technology company, which is developing healthier specialty food ingredients and food crops using gene-editing technology.   Founded in 2010, the Roseville, Minnesota-based company is doing what farmers and botanists have been doing for hundreds of years: choosing the best crops and breeding them to make higher-yielding plants.

Calyxt powers advances in plant sciences, crop traits and building robust portfolio of products

Calyxt Inc (NASDAQ:CLXT) shares jumped Tuesday after an analyst at Canaccord Genuity Capital markets doubled the firm's price target for the company from $8 to $16 and reiterated a "Buy" rating in a note to clients published late Monday. The firm's increasingly bullish stance follows Calyxt's decision in December to sell all 2020 grain production of its high oleic soybean to agriculture giant Archer-Daniels-Midland Company (NYSE:ADM).

Calyxt shares climb after Canaccord analyst doubles price target to $16, repeats 'Buy' rating

Does Calyxt (CLXT) have what it takes to be a top stock pick for momentum investors? Let's find out.

Are You Looking for a Top Momentum Pick? Why Calyxt (CLXT) is a Great Choice

Calyxt (CLXT) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Moving Average Crossover Alert: Calyxt (CLXT)

Here's Why Calyxt (CLXT) is a Great Momentum Stock to Buy

Between these seven genetic editing pioneers, you have the widest exposure to the biggest scientific breakthrough of the century. The post 7 CRISPR Stocks for the Future of Medicine appeared first on InvestorPlace.

News for Calyxt Stock (CLXT)